1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
633CD41DAF7DE85E585257C59007420D0
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-innovative-payer-market-research-influence-of-aco-and-idn-healthoutcomes-and-structure-roles-and-resources?opendocument
18
19opendocument
2034.235.143.190
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Managed Care Payer Market Research

Innovative Payer Market Research: The Influence of ACOs & IDNs, Health Outcomes and Structure, Roles and Resources

ID: 5289


Features:

24 Info Graphics

12 Data Graphics

150+ Metrics

5 Narratives


Pages/Slides: 45


Published: 2014


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
STUDY OVERVIEW

The influence of public and private payers has increased dramatically and, consequently, a large percentage of pharma's top line revenues now flow from payers. Likewise, groups such as Accountable Care Organizations and Integrated Delivery Networks - while still relatively new - also are important to the biopharmaceutical industry because they affect the cost and utilization of prescriptions for large groups of patients.

Best Practices, LLC conducted this research to help organizations understand the drivers and decision-making of ACOs and IDNS. This study also highlights how companies are communicating and coordinating payer research efforts; how they are adjusting in a world increasingly focused on health outcomes and how companies' payer market research groups are using structure, roles and resources to meet payer market research needs.

KEY TOPICS

  • Study Overview
  • Key Findings & Trends
  • ACOs & IDNs are rising in importance
  • Cross-functional collaboration and Communication are critical
  • Optimizing Payer Research Structure, Roles & Resources
  • Preparing to Compete in an outcomes-oriented world
SAMPLE KEY METRICS
  • Importance rating for different payer groups and ACOs & IDNs over the next two years
  • Market research approaches used to understand ACO and IDN decision-making
  • Frequency of market research group meetings with internal stakeholders that interact with payers
  • Anticipated staffing and investment growth/reduction for payer market research group over next two years
  • Percentage of market research budget allocated to payer market research over the past year
  • Structure of U.S. managed market research group
  • Anticipated growth/reduction of resources for four comparative effectiveness research types during the next two years
SAMPLE KEY FINDINGS
Companies Are at Different Levels of Readiness on ACOs/IDNs:
  • Nearly two-thirds of respondents are exploring opportunities to support ACOs
  • Half study how ACOs and IDNs evaluate products in a therapeutic area
  • Approaches for researching ACOs are varied and exist along a continuum from a wait-and-see approach to creating a dedicated function
METHODOLOGY

The research employed a data gathering approach that reaps quantitative & qualitative data from 38 payer research leaders. More than half of the participants represent pharma or biotech companies, and another quarter come from medical device companies. Five selected participants were interviewed to add qualitative depth to the study.

Industries Profiled:
Pharmaceutical; Health Care; Insurance; Medical Device; Market Research; Diagnostic; Education; Consumer Products; Communications; Consulting


Companies Profiled:
Abbott Diabetes Care; Abbott Nutrition; AstraZeneca Neuroscience; CDMI; Biomet; Baxter BioScience; GSW; Joerns Healthcare; Indi; Mako Surgical Corp.; Masimo; Walgreens; Medtronic CRDM; Medtronic Neuromodulation; Hobart Innovations; Health Interactions; Xcenda


If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.